Plain-English translation of NCT05073926 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether rifampicin, a shorter 4-month preventive treatment for latent tuberculosis, causes bacteria called Staphylococcus aureus to become resistant to the medication. Researchers will compare this newer approach with the traditional 6- to 9-month treatment using isoniazide. By swabbing your nose, throat, groin, and any wounds before, during, and after your treatment, the team will monitor whether these common bacteria develop resistance and spread to family members.
More people are choosing the shorter medication because it's easier to complete the full course. However, the medication works against many types of bacteria, not just tuberculosis, and researchers worry that widespread use could cause common skin bacteria to become resistant to the treatment—making it harder to fight infections in the future.
You likely qualify if…
You likely don't qualify if…
You will take your prescribed medication by mouth once daily for either 4 or 9 months, depending on which treatment your doctor recommends. You'll have swabs collected from your nose, throat, groin, and any wounds at several time points—before you start, during your treatment, and after you finish. If you develop any resistant bacteria, household members may also be asked to have swabs taken to check if the bacteria has spread. The study uses genetic testing to understand how the bacteria change over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Sweden
Enrollment target
~100 participants
Started
September 2021
Primary completion
December 2026
Age range
16 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anton Reepalu, PhD
Region Skane
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.